ইউরোপীয় ইউনিয়ন - পোলিশ - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - Środki przeciwnowotworowe - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

ইউরোপীয় ইউনিয়ন - পোলিশ - EMA (European Medicines Agency)

astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - Środki przeciwnowotworowe - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.

ইউরোপীয় ইউনিয়ন - পোলিশ - EMA (European Medicines Agency)

serb sas - glucarpidase - metabolic side effects of drugs and substances - wszystkie inne produkty terapeutyczne - voraxaze is indicated to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk of methotrexate toxicity.

ইউরোপীয় ইউনিয়ন - পোলিশ - EMA (European Medicines Agency)

pfizer europe ma eeig  - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.

ইউরোপীয় ইউনিয়ন - পোলিশ - EMA (European Medicines Agency)

sanofi b.v. - olipudase alfa - acid sphingomyelinase deficiency (asmd) type a/b or type b - inne przewodu pokarmowego i przemianę materii narzędzia, - xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-central nervous system (cns) manifestations of acid sphingomyelinase deficiency (asmd) in paediatric and adult patients with type a/b or type b.

ইউরোপীয় ইউনিয়ন - পোলিশ - EMA (European Medicines Agency)

amryt pharmaceuticals dac - dry extract from birch bark (der 5-10 : 1), extraction solvent n-heptane 95% (w/w) - epidermolysis bullosa dystrophica; epidermolysis bullosa, junctional - preparaty do leczenia ran i owrzodzeń - treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (eb) in patients 6 months and older.

ইউরোপীয় ইউনিয়ন - পোলিশ - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - szpiczak mnogi - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

ইউরোপীয় ইউনিয়ন - পোলিশ - EMA (European Medicines Agency)

immunocore ireland limited - tebentafusp - uveal neoplasms - Środki przeciwnowotworowe - kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (hla)-a*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

ইউরোপীয় ইউনিয়ন - পোলিশ - EMA (European Medicines Agency)

biomarin international limited - valoctocogene roxaparvovec - antykrościeryczne - treatment of severe haemophilia a (congenital factor viii deficiency) in adult patients without a history of factor viii inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (aav5).

ইউরোপীয় ইউনিয়ন - পোলিশ - EMA (European Medicines Agency)

novartis europharm limited - asciminib hydrochloride - białaczka, mielogenna, przewlekła, bcr-abl pozytywna - Środki przeciwnowotworowe - scemblix is indicated for the treatment of adult patients with philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (ph+ cml cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.